• Explore /
  • Poster
  • / A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody.

A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody.

Abstract Poster

Authors

null

Taiji Koyama

Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe-Shi, Japan

Taiji Koyama , Naomi Kiyota , Yoshinori Imamura , Shogen Boku , Nobuhiro Shibata , Hironaga Satake , Kaoru Tanaka , Hidetoshi Hayashi , Shigemichi Iwae , Takuma Onoe , Yukinori Asada , Tomoko Yamazaki , Taku Nose , Shinya Ohata , Shiro Kimbara , Yoshiaki Nagatani , Hironobu Minami

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

jRCTs051200040

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 6032)

DOI

10.1200/JCO.2023.41.16_suppl.6032

Abstract #

6032

Poster Bd #

24

Abstract Disclosures

Similar Posters

First Author: Changgong Zhang

First Author: Jared Cohen

First Author: Jianqing Zhu

First Author: Anne C. Chiang